Related Experiment Video
Updated: Jun 13, 2026
11:17
Thoracoscopic Extended Right Middle Plus Lower Sleeve Lobectomy for Non-Small-Cell Lung Cancer
Published on: February 27, 2026
Managing the patient with borderline resectable lung cancer
Ani Balmanoukian1, David S Ettinger
1The Johns Hopkins School of Medicine, Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, USA.
Oncology (Williston Park, N.Y.)
|April 17, 2010
Summary
Treatment for locally advanced non-small-cell lung cancer (NSCLC) involves varied options. An individualized, multimodality approach is crucial for optimal outcomes in stage IIIA/IIIB NSCLC.
Area of Science:
- Oncology
- Thoracic Surgery
- Radiation Oncology
Background:
- Locally advanced non-small-cell lung cancer (NSCLC) presents heterogeneity in stages IIIA and IIIB.
- Treatment strategies for NSCLC are diverse, including surgery, chemotherapy, and radiation-based therapies.
Observation:
- Surgery is effective for specific T3/T4 N0/N1 stages with intrapulmonary spread.
- Chemotherapy suits minimal mediastinal lymph node involvement.
- Concurrent induction chemoradiation is indicated for bulky nodal disease before resection.
Findings:
- Concurrent definitive chemoradiation or radiation is for non-surgical candidates.
- Optimal therapy selection depends on disease stage, patient age, and performance status.
Implications:
- Individualized, multimodality treatment plans are essential for stage IIIA/IIIB NSCLC.
- Tailoring therapy to patient-specific factors improves management of advanced lung cancer.
